InspireMD (NSPR) AI Stock Analysis

• Market Cap: $94.29M
• Dividend Yield: N/A
• Average Volume (3M): 102.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.15
• Revenue Growth: 7.60%
• EPS Growth: -0.78%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 41,720,660
• 10 Day Avg. Volume: 68,719
• 30 Day Avg. Volume: 102,589
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 14.13
• Enterprise Value/Gross Profit: 67.09
• Enterprise Value/Ebitda: -2.38
• 1Y Price Target: $4.00
• Price Target Upside: 76.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $2.50 ▲(10.62% Upside)

InspireMD's overall score is primarily impacted by its financial performance and valuation challenges. Despite positive developments from the earnings call, such as FDA approval and strong market reception, the company's ongoing profitability and cash flow issues, along with a bearish technical outlook, weigh heavily on the stock's attractiveness.

Positive Factors

FDA Approval for CGuard Prime

The FDA approval is a transformative milestone, enabling U.S. commercial launch and expanding market access, which can drive long-term revenue growth and market leadership in carotid interventions.

Strong Cash Position

A strengthened cash position supports InspireMD's growth strategy and commercial launch efforts, providing financial flexibility to invest in market expansion and R&D, crucial for long-term sustainability.

Progress in Clinical Pipeline

Advancements in the clinical pipeline indicate potential for expanded product indications and market reach, enhancing InspireMD's competitive position and future revenue streams.

Negative Factors

Increased Operating Expenses

Rising operating expenses, driven by U.S. expansion efforts, could pressure profitability and cash flow, challenging InspireMD's ability to achieve sustainable financial performance.

Decreased Gross Profit

A decline in gross profit and margin suggests challenges in cost management, which may impact InspireMD's ability to improve profitability and reinvest in growth initiatives.

Net Loss Increase

An increasing net loss highlights financial challenges, potentially limiting InspireMD's capacity to fund strategic initiatives and necessitating careful management of resources to sustain operations.

InspireMD Business Overview & Revenue Model

Company Description

InspireMD (NSPR) is a medical device company specializing in innovative solutions for the treatment of cardiovascular diseases. The company is primarily focused on the development and commercialization of its proprietary CGuard™ embolic protection system, which is designed to improve patient outcomes during carotid artery procedures. InspireMD operates within the healthcare sector, targeting hospitals and healthcare providers by offering advanced medical technologies that enhance procedural safety and efficacy.

How the Company Makes Money

InspireMD generates revenue primarily through the sale of its CGuard™ embolic protection systems to hospitals and medical institutions. The company typically employs a direct sales model, complemented by partnerships with distributors to expand its market reach. Key revenue streams include product sales, with potential for recurring revenue through the sale of consumables related to its devices. Additionally, the company may benefit from strategic collaborations with other healthcare entities, which can include co-development agreements or distribution partnerships that enhance market access and drive sales growth.

InspireMD Financial Statement Overview

Summary

InspireMD shows revenue growth but faces significant profitability and cash flow challenges. The company maintains a strong equity position, yet ongoing operational losses and negative cash flows pose potential risks.

Income Statement

InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.

Cash Flow

InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.07M	7.01M	6.21M	5.17M	4.50M	2.48M
Gross Profit	1.49M	1.51M	1.81M	1.12M	754.00K	83.00K
EBITDA	-41.96M	-33.22M	-20.91M	-18.52M	-14.55M	-10.23M
Net Income	-41.38M	-32.01M	-19.92M	-18.49M	-14.92M	-10.54M
Balance Sheet
Total Assets	33.34M	46.81M	47.64M	24.65M	39.71M	17.78M
Cash, Cash Equivalents and Short-Term Investments	19.37M	34.64M	39.02M	17.80M	34.04M	12.64M
Total Debt	3.42M	2.34M	1.59M	1.61M	1.20M	999.00K
Total Liabilities	13.10M	10.72M	8.14M	7.26M	6.18M	5.61M
Stockholders Equity	20.24M	36.09M	39.50M	17.39M	33.53M	12.16M
Cash Flow
Free Cash Flow	-31.24M	-23.27M	-16.76M	-16.02M	-13.55M	-9.17M
Operating Cash Flow	-29.57M	-21.87M	-16.38M	-15.54M	-13.21M	-9.08M
Investing Cash Flow	9.34M	12.64M	-16.09M	8.44M	-22.46M	-187.00K
Financing Cash Flow	3.24M	18.45M	37.53M	-140.00K	35.03M	16.39M

InspireMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Negative. The current price of 2.26 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 2.40, and below the 200-day MA of 2.56, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 14.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NSPR.

InspireMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XTNT	57 Neutral	$112.14M	-22.44	-9.80%	―	15.16%	-39.18%
EDAP	55 Neutral	$88.99M	-4.15	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APYX	50 Neutral	$121.40M	-7.11	-156.90%	―	-5.14%	44.86%
ANIK	46 Neutral	$144.33M	-2.42	-22.91%	―	-25.85%	18.18%
NSPR	45 Neutral	$94.29M	-2.72	-123.51%	―	7.60%	-0.78%
VANI	44 Neutral	$95.98M	-3.67	-177.75%	―	―	4.91%

InspireMD Corporate Events

InspireMD Appoints Dan Dearen to Board of Directors

On September 17, 2025, InspireMD announced the appointment of Dan Dearen to its Board of Directors. With nearly 40 years of experience in the medical device and life sciences sectors, Dearen is expected to bring valuable financial expertise and strategic insight to the company. His appointment comes at a pivotal time as InspireMD continues the U.S. commercial launch of its CGuard Prime stent system, which has received FDA approval. This strategic move is anticipated to enhance InspireMD’s market position and support its growth ambitions in the carotid intervention market.

The most recent analyst rating on (NSPR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Inc. Navigates Trade Policy Risks with U.S. Manufacturing Plans

InspireMD Inc. faces significant business risks due to potential changes in trade policies, including tariffs and customs regulations, which could adversely impact its reputation, financial condition, and operational results. The company’s reliance on manufacturing and distributing its CGuard Prime carotid stent system from Israel to the U.S. market makes it vulnerable to any new tariffs or changes in trade agreements between the two countries. Such developments could lead to increased costs, affecting gross margins and pricing flexibility, while also introducing logistical challenges and supply chain modifications. These trade-related risks underscore the importance of InspireMD’s ongoing efforts to establish manufacturing operations in the United States with Aptyx Interventional Systems.

InspireMD Inc. Reports Q2 2025 Earnings and Regulatory Milestones

InspireMD Inc. is a medical device company specializing in the development and commercialization of its proprietary MicroNet™ stent platform technology, primarily targeting complex vascular and coronary diseases. The company operates within the healthcare sector, with a unique focus on embolic protection in stenting procedures.

InspireMD’s Earnings Call: FDA Approval and Financial Challenges

InspireMD Inc. recently held its earnings call, which was marked by a mix of optimism and caution. The company celebrated significant achievements, including FDA approval for its CGuard Prime Carotid Stent System and successful fundraising efforts, which position it for growth in the U.S. market. However, these positive developments were tempered by financial challenges, such as increased operating costs, a widened net loss, and delays in product launches.

InspireMD Reports Q2 2025 Financial Results and Milestones

On August 5, 2025, InspireMD reported its financial results for the second quarter and the first half of 2025, highlighting significant milestones including FDA approval and the U.S. launch of its CGuard Prime carotid stent system. The company also secured $58 million through equity placement and warrant exercises, supporting its growth initiatives. Despite a slight increase in revenue, the company faced a net loss due to increased operating expenses related to sales force expansion and product launch preparations. InspireMD’s strategic moves are expected to position it as a leader in carotid artery disease treatment.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Raises $40.1M in Private Placement Offering

On July 30, 2025, InspireMD entered into a securities purchase agreement for a private placement offering, raising approximately $40.1 million through the sale of common stock and pre-funded warrants. The offering is expected to close by August 1, 2025, and includes a registration rights agreement to file a resale registration statement with the SEC. Additionally, InspireMD announced the full exercise of its Series I warrants, generating $17.9 million in gross proceeds, and the combined financings of $58 million will bolster the company’s balance sheet to commercialize its FDA-approved CGuard Prime carotid stent in the U.S. market. The company aims to use the proceeds for operations, including sales, marketing, and research and development, positioning itself as a leader in the carotid intervention market.

The most recent analyst rating on (NSPR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.